Multi-Site Momentum and Therapeutic Diversification Shape India’s Research Landscape

The Q1 2026 edition of IndiaTrialPulse by StriderDCT analyzed how India’s clinical trial ecosystem evolved between January and March 2026.

The quarter reflected growing multi-site momentum, strong domestic research participation, and expanding therapeutic diversity.

Q1 2026 at a Glance

• 3112 total clinical trials were registered
• 121 multi-site trials were recorded
• Oncology remained the leading therapeutic area
• Indian Pharma and Global Pharma drove major sponsor activity
• Tier 2 city participation continued to rise

What This Indicates

• India’s clinical research ecosystem is steadily becoming more distributed, scalable, and execution-ready.
• The consistent participation across therapeutic areas, sponsors, and geographic regions highlights growing ecosystem maturity and stronger operational capabilities.
• IndiaTrialPulse aims to bring structured visibility into these evolving trends through data-backed clinical trial intelligence.